- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02727166
Effect of Chicory-derived Inulin on Abdominal Sensations and Bowel Motor Function
March 29, 2016 updated by: Hospital Universitari Vall d'Hebron Research Institute
Efecto de Fructanos Paralelamente Hidrolizados Provenientes de Achicoria Sobre Las Sensaciones Abdominales
Subjects with gas-related complaints exhibit impaired handling of intestinal gas loads and we hypothesized that inulin would have a beneficial effect.
Aim: to determine the effect of a prebiotic chicory-derived inulin-type fructan on the tolerance of intestinal gas.
Methods.
Placebo-controlled, parallel, randomized and double-blind trial study.
Subjects with abdominal symptoms and reduced tolerance of intestinal gas (selected by a pre-test) will receive either inulin (8 g/d, n=18) or maltodextrin as a placebo (8 g/d, n=18) for 4 wk.
A gas challenge test (4 h jejunal gas infusion at 12 mL/min while measuring abdominal symptoms and gas retention for 3 h) will be performed before and at the end of the intervention phase.
Gastrointestinal symptoms and bowel habits (using daily questionnaires for 1 wk) and fecal bifidobacteria counts will be measured before and at the end of the intervention.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
67
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- negative sensation of digestive well-being (score ≤ 1 on at least 2 of the 6 evaluation days, scored on a - 5 / +5 scale.
- poor tolerance of a gas challenge test (abdominal perception score ≥ 3, on a 0-6 scale, for at least three 15-min time points over the last 90 minutes of the 180-minute-long intestinal gas infusion test).
Exclusion Criteria:
- antibiotic intake,
- exceptional diets,
- changes in dietary habits or intake of Ca supplements over the preceding month.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inulin 8 g/d
Mixture of oligo- and polysaccharides composed of fructose units connected by β (2→1) links with a total number of fructose and glucose units ranging between 2 and 70.
|
Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
|
Placebo Comparator: maltodextrine 8 g/d
|
Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perception of intestinal gas infusion
Time Frame: 60 last min of the 180 min gas infusion test
|
Effect of inulin intake (change from baseline with inulin versus placebo) on the tolerance of the gas challenge test, measured as the perception score of digestive sensations during the gas challenge test.
At each time point, the highest score instead of the mean or cumulative scores will be computed for comparisons; these scores will be averaged over the last 60 min of the test in each subject; the differences between basal and intervention periods (inulin or placebo) will be calculated.
|
60 last min of the 180 min gas infusion test
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intestinal gas retention
Time Frame: 60 last min of the 180 min gas infusion test
|
Effect of inulin intake (change from baseline with inulin versus placebo) on the volume of gas retention (volume infused minus volume evacuated) measured as the average value over the last 60 min of the gas infusion test.
|
60 last min of the 180 min gas infusion test
|
Digestive well-being
Time Frame: 6 last days of intervention
|
Effect of inulin intake (change from baseline with inulin versus placebo) on digestive well-being measured by daily questionnaires on - 5 to + 5 score scales and averaged over 6 days.
|
6 last days of intervention
|
Abdominal discomfort
Time Frame: 6 last days of intervention
|
Effect of inulin intake (change from baseline with inulin versus placebo) on abdominal discomfort measured by daily questionnaires on 0 to 10 score scales and averaged over 6 days.
|
6 last days of intervention
|
Bowel habit
Time Frame: 6 last days of intervention
|
Effect of inulin intake (change from baseline with inulin versus placebo) on the number of bowel movements measured by daily questionnaires during 6 days.
|
6 last days of intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Fernando Azpiroz, MD, Vall d'Hebron Research Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2010
Primary Completion (Actual)
July 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
March 18, 2016
First Submitted That Met QC Criteria
March 29, 2016
First Posted (Estimate)
April 4, 2016
Study Record Updates
Last Update Posted (Estimate)
April 4, 2016
Last Update Submitted That Met QC Criteria
March 29, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR(AG)168/2010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Gastrointestinal Disorders
-
Umeå UniversityRecruitingFunctional Gastrointestinal DisorderSweden
-
The University of Texas Medical Branch, GalvestonCompletedGastrointestinal Disorders, Functional
-
Dr Anne PayneUniversity of LondonUnknownFunctional Gastrointestinal Disorders in ChildrenUnited Kingdom
-
Chang Gung Memorial HospitalNew Bellus EnterprisesUnknownNeoplasm | Functional Gastrointestinal DisorderTaiwan
-
BayerCompletedA Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world SettingFunctional Dyspepsia | Irritable Bowel Syndrome | Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional DyspepsiaGermany
-
Chinese University of Hong KongCompletedFunctional Gastrointestinal DisorderHong Kong
-
Aarhus University HospitalKarolinska InstitutetCompletedFunctional Gastrointestinal DisordersDenmark
-
Bausch Health Americas, Inc.CompletedFunctional Gastrointestinal DisordersUnited States
-
Danone Asia Pacific Holdings Pte, Ltd.ObvioHealthCompletedFunctional Gastrointestinal DisordersThailand
-
BayerCompletedFunctional Gastrointestinal DisordersGermany
Clinical Trials on Inulin
-
Scottish Universities Environmental Research CentreUniversity of Glasgow; NHS Greater Clyde and GlasgowCompletedObesity | OverweightUnited Kingdom
-
Eskisehir Osmangazi UniversityUnknownFunctional Constipation
-
Maastricht University Medical CenterCompleted
-
Imperial College LondonUniversity of GlasgowCompletedAppetite Regulation | Healthy Obesity, MetabolicallyUnited Kingdom
-
University of Illinois at Urbana-ChampaignRenal Research InstituteCompletedBone Diseases, Endocrine | Nutritional and Metabolic DiseasesUnited States
-
Augusta UniversityAmerican Gastroenterological Association FoundationCompletedInvestigation of Dietary Absorptive Capacity of Fructans in Healthy Subjects - A Dose Response StudyHealthy VolunteersUnited States
-
University of ReadingUnknownOverweight and ObesityUnited Kingdom
-
Second Xiangya Hospital of Central South UniversityNot yet recruitingType 1 Diabetes Mellitus | Autoimmune DiabetesChina
-
National Institute of Diabetes and Digestive and...University of Pennsylvania; George Washington UniversityUnknownChronic Kidney DiseasesUnited States
-
CindetecNucitec SA de CVCompleted